Investment
Features
FeesSafety
Academy
More
Pluang+

Compare GraniteShares 2x Long COIN Daily ETF (CONL) vs DexCom, Inc. (DXCM) Price & Performance

GraniteShares 2x Long COIN Daily ETFTrade
DexCom, Inc.Trade

Price performance (Past 24H)

Key statistics

GraniteShares 2x Long COIN Daily ETF vs DexCom, Inc. — how do they compare? GraniteShares 2x Long COIN Daily ETF trades at $5.33, while DexCom, Inc. trades at $74.41 (market cap $28.60B). The key difference: DexCom, Inc. is trading nearer its 52-week high, GraniteShares 2x Long COIN Daily ETF nearer its low. Which is the better fit depends on your goals.

CONLDXCM
Sector
Leveraged / InverseHealth
52-Week High
$64.57$89.53
52-Week Low
$4.09$54.84
Market Cap
$28.60B
Enterprise Value
$27.57B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

GraniteShares 2x Long COIN Daily ETF

CONL, the GraniteShares 2x Long COIN Daily ETF, trades at $4.85, down 2.02% on the day, reflecting a challenging year-to-date performance. Technical indicators are predominantly bearish, with moving averages signaling strong selling pressure, while oscillators remain neutral. Recent news highlights the fund's volatility, with significant losses tied to Coinbase stock swings and leveraged daily resets.

The outlook remains highly speculative, offering potential for explosive gains if Bitcoin rallies but carrying substantial risk from daily leverage decay and Coinbase volatility. Investors face amplified losses in downturns, making this suitable only for short-term traders with high risk tolerance.

DexCom, Inc.

DXCM trades at $76.35, up 1.85% today, with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with 17.93% net income margin and consistent earnings beats. Recent regulatory approvals for G7 15-day CGM in Canada and pediatric clearance for Stelo OTC system highlight growth catalysts. Revenue growth accelerated to $4.66 billion in 2025, up from $4.0 billion in 2024.

DXCM presents a compelling growth story with expanding CGM market access and strong analyst support (80% buy ratings). Key risks include GLP-1 adoption impact on core market and execution of Type 2 non-insulin patient expansion. The stock trades at a premium valuation (P/E 32.76) but offers upside to consensus target of $83.78. Near-term focus on Q2 2026 earnings release July 30.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About GraniteShares 2x Long COIN Daily ETF

CONL is a leveraged ETF that seeks to provide two times (2x) the daily performance of Coinbase Global (COIN) stock. It is designed for investors seeking magnified short-term exposure to the price movements of Coinbase.

Read more on CONL

About DexCom, Inc.

Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.

Read more on DXCM